Novo Nordisk, maker of Ozempic, applied for FDA approval for a weight loss pill, less than a week after rival Eli Lilly's clinical trial success.

The U.S. Food and Drug Administration and the pharmaceutical company Novo Nordisk are urging consumers to be on the lookout ...

Patent expiry and pricing pressure across the diabetes market remain a concern. Nevertheless, Novo Nordisk’s diabetes drugs Ozempic and Rybelsus and obesity drug Wegovy are performing well ...

It has been a tough period for Novo Nordisk shareholders. In the summer of 2024, the share price was over DKK 1,000 per share. Now it is approaching DKK 400.The latest dip comes on Wednesday morning ...

In this exclusive interview, Business Today speaks with Vikrant Shrotriya, Managing Director of Novo Nordisk India ... a valuable option for obesity care. For diabetes management, we already ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Dividends and the share repurchase programs of the Novo Group companies (Novo Nordisk and Novonesis) totaled 23 billion Danish kroner, and Returns from the Investment Portfolio generated an income ...

Novo Nordisk has experienced a 50% drop due to potential tariffs and recent clinical trial results but remains strong in diabetes treatment, insulin, and GLP-1 products. I outline the bull case ...

Bagsværd, Denmark, 29 March 2025 – Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus ® (oral semaglutide) significantly reduced the ...

Novo Nordisk (NVO) announced on Saturday that a late-stage trial for its popular weight loss therapy Ozempic in adults with type 2 diabetes and a vascular disorder known as peripheral artery ...